Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

Michel Jadoul; Marina C. Berenguer; Wahid Doss; Fabrizio Fabrizi; Jacques Izopet; Vivekanand Jha; Nassim Kamar; Bertram L. Kasiske; Ching Lung Lai; José M. Morales; Priti R. Patel; Stanislas Pol; Marcelo O. Silva; Ethan M. Balk; Craig E. Gordon; Amy Earley; Mengyang Di; Paul Martin

doi:10.1016/j.kint.2018.06.011

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

Michel Jadoul, Marina C. Berenguer, Wahid Doss, Fabrizio Fabrizi, Jacques Izopet, Vivekanand Jha, Nassim Kamar, Bertram L. Kasiske, Ching Lung Lai, José M. Morales, Priti R. Patel, Stanislas Pol, Marcelo O. Silva, Ethan M. Balk, Craig E. Gordon, Amy Earley, Mengyang Di, Paul Martin

Research output: Contribution to journal › Article › peer-review

64 Scopus citations

Abstract

Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

Original language	English
Pages (from-to)	663-673
Number of pages	11
Journal	Kidney International
Volume	94
Issue number	4
DOIs	https://doi.org/10.1016/j.kint.2018.06.011
State	Published - Oct 2018
Externally published	Yes

Keywords

KDIGO
antivirals
chronic kidney disease
cryoglobulinemia
dialysis
direct-acting antivirals
glomerular diseases
guideline
hemodialysis
hepatitis C virus
infection control
kidney transplantation
liver testing
nosocomial transmission
screening
systematic review

Access to Document

10.1016/j.kint.2018.06.011

Cite this

Jadoul, M., Berenguer, M. C., Doss, W., Fabrizi, F., Izopet, J., Jha, V., Kamar, N., Kasiske, B. L., Lai, C. L., Morales, J. M., Patel, P. R., Pol, S., Silva, M. O., Balk, E. M., Gordon, C. E., Earley, A., Di, M., & Martin, P. (2018). Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney International, 94(4), 663-673. https://doi.org/10.1016/j.kint.2018.06.011

@article{758c01e44e63421b9f7f8d8009a6c333,

title = "Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management",

abstract = "Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.",

keywords = "KDIGO, antivirals, chronic kidney disease, cryoglobulinemia, dialysis, direct-acting antivirals, glomerular diseases, guideline, hemodialysis, hepatitis C virus, infection control, kidney transplantation, liver testing, nosocomial transmission, screening, systematic review",

author = "Michel Jadoul and Berenguer, {Marina C.} and Wahid Doss and Fabrizio Fabrizi and Jacques Izopet and Vivekanand Jha and Nassim Kamar and Kasiske, {Bertram L.} and Lai, {Ching Lung} and Morales, {Jos{\'e} M.} and Patel, {Priti R.} and Stanislas Pol and Silva, {Marcelo O.} and Balk, {Ethan M.} and Gordon, {Craig E.} and Amy Earley and Mengyang Di and Paul Martin",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors",

year = "2018",

month = oct,

doi = "10.1016/j.kint.2018.06.011",

language = "English",

volume = "94",

pages = "663--673",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "4",

}

Jadoul, M, Berenguer, MC, Doss, W, Fabrizi, F, Izopet, J, Jha, V, Kamar, N, Kasiske, BL, Lai, CL, Morales, JM, Patel, PR, Pol, S, Silva, MO, Balk, EM, Gordon, CE, Earley, A, Di, M & Martin, P 2018, 'Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management', Kidney International, vol. 94, no. 4, pp. 663-673. https://doi.org/10.1016/j.kint.2018.06.011

TY - JOUR

T1 - Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline

T2 - welcoming advances in evaluation and management

AU - Jadoul, Michel

AU - Berenguer, Marina C.

AU - Doss, Wahid

AU - Fabrizi, Fabrizio

AU - Izopet, Jacques

AU - Jha, Vivekanand

AU - Kamar, Nassim

AU - Kasiske, Bertram L.

AU - Lai, Ching Lung

AU - Morales, José M.

AU - Patel, Priti R.

AU - Pol, Stanislas

AU - Silva, Marcelo O.

AU - Balk, Ethan M.

AU - Gordon, Craig E.

AU - Earley, Amy

AU - Di, Mengyang

AU - Martin, Paul

PY - 2018/10

Y1 - 2018/10

N2 - Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

AB - Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.

KW - KDIGO

KW - antivirals

KW - chronic kidney disease

KW - cryoglobulinemia

KW - dialysis

KW - direct-acting antivirals

KW - glomerular diseases

KW - guideline

KW - hemodialysis

KW - hepatitis C virus

KW - infection control

KW - kidney transplantation

KW - liver testing

KW - nosocomial transmission

KW - screening

KW - systematic review

UR - http://www.scopus.com/inward/record.url?scp=85053346985&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2018.06.011

DO - 10.1016/j.kint.2018.06.011

M3 - Article

C2 - 30243313

AN - SCOPUS:85053346985

SN - 0085-2538

VL - 94

SP - 663

EP - 673

JO - Kidney International

JF - Kidney International

IS - 4

ER -

Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management

Abstract

Keywords

Access to Document

Fingerprint

Cite this